Medicare to Cover GLP1 Weight Loss Drugs at $50

The Medicare GLP-1 Bridge is a temporary federal pilot that lets qualifying Medicare beneficiaries pay just 50 dollars a month for certain weight loss GLP-1 drugs, including Wegovy and Zepbound, starting July 1 and running through December 31, 2027.

At a Glance

• The Centers for Medicare and Medicaid Services (CMS) is running the demonstration from July 1 through December 31, 2027.
• Eligible drugs are limited to specific formulations of Foundayo, Wegovy, and Zepbound.
• KFF estimates up to 3.8 million Medicare beneficiaries could qualify, based on 2023 data.
• The flat 50 dollar copay sits outside normal Part D cost sharing rules.
• Applicants need a doctor's prescription and, in some cases, prior authorization from a pharmacy.

Why Medicare Is Opening the Door to GLP-1s

Medicare has historically refused to pay for drugs prescribed solely for weight loss. GLP-1 medications like Wegovy and Zepbound were only covered when tied to conditions such as type 2 diabetes or cardiovascular disease. The new Bridge program carves out a narrow, time limited exception aimed specifically at obesity and weight management.

Chris Klomp, who directs Medicare and serves as chief counselor at the Department of Health and Human Services, framed the initiative as an effort to smooth out access. In the program's announcement, he said GLP-1 drugs can transform life for people dealing with obesity and related health problems, and that the goal is to make getting these medications more predictable and consistent for seniors while improving value across the health system.

Which Drugs Qualify and Who Can Enroll

The list of approved medications is narrow for now. It covers Foundayo in tablet form, Wegovy as either a tablet or injection, and Zepbound delivered through the Kwikpen device. Other GLP-1 products are not included in this round.

Eligibility runs through Medicare Part D, so beneficiaries in any state or territory with a standalone drug plan or a Medicare plan bundling Part D coverage can apply. People who already qualify for GLP-1 coverage through Medicare because of diabetes, sleep apnea, or fatty liver disease are excluded from the Bridge, since they can already access these drugs through existing channels.

Beyond that carve out, applicants must meet one of three clinical thresholds. A body mass index of 35 or higher qualifies on its own. A BMI between 30 and 34.99 qualifies if paired with conditions like diastolic heart failure, hypertension, stage 3a or more advanced chronic kidney disease, prediabetes, a prior heart attack or stroke, or blocked arteries in the arms or legs. A BMI between 27 and 29.99 qualifies alongside prediabetes, a previous heart attack or stroke, or blocked arm or leg arteries.

How Much Beneficiaries Could Save

The savings potential is significant when compared with current retail pricing. On TrumpRx, the discount platform launched by the Trump administration, the Wegovy tablet starts at 149 dollars monthly, and the Zepbound Kwikpen starts at 299 dollars. GoodRx lists Foundayo starting at 149 dollars and the Wegovy injection at a minimum of 199 dollars. Those figures are floor prices; costs climb further at higher doses or through certain providers.

That gap illustrates why officials expect strong interest even though the flat fee will not count toward a beneficiary's yearly deductible, out of pocket limit, or eligibility for the Medicare Prescription Payment Plan or low income subsidies.

Applying for the Program

Getting enrolled starts with a doctor's prescription for a covered GLP-1 aimed at weight loss or weight management. The prescribing doctor sends that order to a pharmacy, which may then request a prior authorization to confirm the patient meets the clinical criteria and that the drug is intended for weight related use rather than another condition. Neither doctors nor pharmacies have to formally opt into the program to participate.

Once approved, patients get single month refills at the same 50 dollar rate, with room for dose adjustments, all the way through the program's scheduled end in December 2027.

What Happens When the Bridge Program Expires

CMS estimates put eligibility in the